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ABSTRACT
Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is 
commonly observed in triple negative breast cancer (TNBC), leading to activation of 
the phosphoinositide 3-kinase (PI3K) signaling to promote tumor cell growth and 
chemotherapy resistance. In this study, we investigated whether adding a pan-PI3K 
inhibitor could improve the cytotoxic effect of eribulin, a non-taxane microtubule 
inhibitor, in TNBC patient-derived xenograft models (PDX) with loss of PTEN, and the 
underlying molecular mechanisms. Three TNBC-PDX models (WHIM6, WHIM12 and 
WHIM21), all with loss of PTEN expression, were tested for their response to BKM120 
and eribulin, alone or in combination in vivo. In addition, the effect of drug treatment 
on cell proliferation and cell cycle progression were also performed in vitro using 
a panel of TNBC cell lines, including 2 derived from PDX models. The combination 
of eribulin and BKM120 led to additive or synergistic anti-tumor effect in 2 of the 3 
PDX models, accompanied by an enhanced mitotic arrest and apoptosis in sensitive 
PDX models. In addition, the combination was synergistic in reducing mammosphere 
formation, and markers for epithelial-mesenchymal transition (EMT). In conclusion, 
PI3K inhibition induces synergistic anti-tumor effect when combined with eribulin, 
by enhancing mitotic arrest and apoptosis, as well as, reducing the cancer stem cell 
population. This study provides a preclinical rationale to investigate the therapeutic 
potential for the combination of PI3K inhibition and eribulin in the difficult to treat 
TNBC. Further studies are needed to identify the biomarkers of response for target 
patient selection.
INTRODUCTION
Triple negative breast cancer (TNBC), defined by the 
lack of estrogen receptor (ER), progesterone receptor (PR) 
and HER2 gene amplification, represents approximately 
15 to 20% of all breast cancer cases and is associated 
with the worst prognosis compared to other breast cancer 
subtypes [1-6]. The lack of molecularly targeted therapy 
and the frequent occurrence of chemotherapy resistance 
render TNBC a significant clinical challenge.
Eribulin mesylate (Halaven®, Eisai Inc) is a non-
taxane microtubule dynamic inhibitor [7] that is Food 
and Drug Administration (FDA) approved for patients 
with metastatic breast cancer who have received at least 
two prior chemotherapeutic regimens in the metastatic 
setting and an anthracycline as well as a taxane in 
either adjuvant or metastatic setting. In the phase III 
EMBRACE study, eribulin was associated with superior 
overall survival (OS) compared with physician's 
choice chemotherapy in this patient population [8]. 
The efficacy of eribulin in TNBC was demonstrated in 
the pooled analysis of 2 phase 3 studies (EMBRACE/
Study 305), which revealed 4.7 months improvement 
in median survival with eribulin compared to control 
chemotherapy (median OS: 12.9 vs 8.2 months; HR 
0.74; P = 0.006) [9]. In addition to the induction of an 
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irreversible mitotic block, eribulin has been shown to 
impact tumor vascular remodeling [10] and inhibition of 
epithelial-to-mesenchymal transition and metastasis in 
experimental models [11] which has been implicated in 
Figure 1: Eribulin in combination with BKM120 induces synergistic anti-tumor effect and target inhibition in 
TNBC cells in vitro. Percentages of cell survival compared to vehicle control following 6 days of treatment with eribulin at indicated 
concentrations, either alone or in combination with BKM120 (500 nM) were plotted for (A) BT549, (B) MDA-MB-231, (C) HCC1806, 
(D) WHIM3, and (E) WHIM12. * indicates p<0.05 and ** indicates p<0.01. The combination of BKM120 and eribulin was significantly 
more effective in reducing cell survival than each agent alone in these cell lines. Panel F shows the Western blot analysis for PI3K pathway 
signaling, EMT, and apoptosis markers on cell lysates from BT549 and MDA-MB-231 following treatment with eribulin and BKM120, 
alone or in combination for 48 hours. Abbreviations: V, Vehicle; B, BKM120; E, Eribulin; C, Combination. Compared to single agents, 
the combination of BKM120 and eribulin was most effective in reducing the levels of pAKT and pS6 (markers of PI3K pathway activity), 
N-Cadherin (EMT marker) and Survivin (an anti-apoptotic protein) and in the induction of apoptosis (Cleaved PARP).
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therapeutic resistance to cancer drugs including growth 
factor receptor and PI3K inhibitors [12].
The phosphoinositide 3-kinase (PI3K) pathway 
plays key regulatory roles in many cellular processes, 
including cell survival, proliferation, differentiation and 
angiogenesis [13, 14]. Hyper activation of the PI3K/
AKT pathway has been associated with TNBC [15, 16]. 
A significantly higher level of Akt phosphorylation has 
been observed in TNBC patient specimens compared with 
non–TNBC cases [15, 17]. Loss of PTEN or INPP4B 
has been the most frequently implicated culprit for such 
activation in TNBC [16, 18-21]. The high frequency of 
PI3K pathway activation in TNBC renders it an attractive 
therapeutic target. In addition, PI3K pathway activation 
has also been associated with chemotherapy resistance 
[22] and inhibition of PI3K pathway activity could 
synergize the cytotoxicity of a variety of chemotherapy 
agents [23-25]. In a cell-based, high-throughput screening 
in a panel of twenty-five human cancer cell lines 
representing a variety of tumor types, the PI3K inhibitor 
BKM120 was identified to exert synergistic killing with 
eribulin in both eribulin sensitive and resistant cancer 
cell lines, 3 of which being TNBC [26]. The objectives of 
this study is to assess the combinatory effect of eribulin 
and BKM120 in TNBC cell lines and patient-derived 
xenograft (PDX) models and to further elucidate the 
underlying molecular mechanisms.
RESULTS
Synergistic anti-tumor effect of eribulin and 
BKM120 through enhanced target inhibition in a 
panel of TNBC cell lines
To assess the anti-tumor effect of BKM120 and 
eribulin, we tested a panel of TNBC cell lines (BT549, 
HCC1806, and MDA-MB-231) as well as two PDX derived 
cell lines (WHIM3 and WHIM12), for their response to 
eribulin (0.1, 0.5 and 1nM) alone or in combination with 
BKM120 (500nM) in vitro. Synergistic anti-tumor effect, 
with combination index (CI) less than 1, between eribulin 
and BKM120 was observed in all the tested TNBC cell lines 
(Figure 1A-1E). Western Blot demonstrated that, compared 
to individual agents, the combination of eribulin and 
BKM120 was most effective in inhibiting PI3K pathway 
signaling, as indicated by reduced pAKT and pS6 in 
BT549 and MDA-MB-231 cells (Figure 1F). Additionally, 
the combination reduced the level of the Epithelial to 
Mesenchymal Transition (EMT) marker N-Cadherin more 
effectively than eribulin alone, reduced the levels of the 
anti-apoptotic protein Survivin, and enhanced apoptosis 
as assessed by cleaved PARP (Figure 1F). Since eribulin 
induces apoptosis by inhibiting mitotic progression, we 
performed cell cycle analysis with flow cytometry, which 
demonstrated that the combination of eribulin and BKM120 
was most effective in inducing G2/M arrest (Figure 2).
Anti-tumor activity of eribulin in combination 
with BKM120 in TNBC PDX models in vivo
To validate the in vitro observation we evaluated 
the anti-tumor and biomarker effect for eribulin 
and BKM120 in TNBC PDX models that we have 
previously characterized [27]. We first performed a 
screening experiments using 1-3 mice per model for the 
combination of eribulin and BKM120 in 6 TNBC PDX 
models, including WHIM2, WHIM4, WHIM6, WHIM12, 
WHIM21, and WHIM30 (Supplementary Figure 1). As 
shown in Figure 3A, tumor volume reduction was observed 
in 5 of the 6 models, including WHIM2 (average -21% 
on day 11), WHIM4 (average -25% on day 15), WHIM6 
(average -18% on day 11), WHIM21 (average -92% on day 
18) and WHIM30 (average -66% on day 22) compared to 
baseline at the best response. To discern the effect of single 
agent versus combination, we treated 3 representative 
models including, WHIM6 (Basal-like, WT TP53), 
WHIM12 (Claudin-low, TP53 p.R248Q, PIK3CA pV105_
E109delinsT) and WHIM21 (Basal-like, TP53 p.P151H), 
all with loss of PTEN expression and relatively high 
PI3K pathway signaling [27] to either vehicle, eribulin, 
BKM120, or the combination of eribulin and BKM120. 
Combination therapy led to added or synergistic anti-tumor 
effect in WHIM6 (Figure 3A). However, no obvious added 
benefit was observed with the combination compared to 
eribulin alone in WHIM12 and WHIM21 (Figure 3B 
and 3C). Since eribulin alone at 1 mg/kg weekly dosing 
potently inhibited xenograft tumor growth, which could 
have prohibited further tumor growth inhibition with the 
addition of BKM120, we reduced the dose of eribulin to 
0.3 mg/kg weekly in WHIM21 to compare its anti-tumor 
effect with or without BKM120. Indeed, the addition 
of BKM120 to the lower dose of eribulin, either given 
concurrently (eribulin on day 1 and BKM120 on days 1-5, 
each week) or sequentially (eribulin on day 1 and BKM120 
on days 2-5, each week) led to more effective tumor 
growth inhibition compared to eribulin alone (Figure 3D).
The combination of eribulin and BKM120 
enhanced mitotic arrest and apoptotic induction 
in TNBC PDX models in vivo
To assess the molecular mechanisms for the 
enhanced anti-tumor effect from the combination of 
BKM120 and eribulin in TNBC in vivo, PDX xenografts 
were harvested on day 3 following treatment with either 
vehicle or eribulin (day 1) and BKM120 (days 1-3) alone 
or in combination and subjected to biomarker analysis. 
Consistent with the in vitro observation for the enhanced 
G2/M phase arrest and apoptosis induction (Figure 1E 
and Figure 2), combination therapy led to more effective 
mitotic arrest, as shown by the increased proportion of 
cells with pHistone H3 staining, and increased apoptosis 
(increased cleaved PARP) in vivo (Figure 4A and 4B). As 
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Figure 2: Eribulin in combination with BKM120 induces G2/M cell cycle arrest more effectively than either agent 
alone in TNBC. Cell Cycle analysis was performed for (A) WHIM12-PDX derived cell line, (B) BT549 and (C) MDA-MB-231 TNBC 
cell lines after treatment with vehicle, or BKM120 and eribulin, alone and in combination. Abbreviations: V, Vehicle; B, BKM120; E, 
Eribulin; C, Combination. The combination of eribulin and BKM120 was most effective in inducing G2/M arrest.
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predicted, treatment with BKM120 reduced PI3K pathway 
signaling indicated by the levels of pAKT and treatment 
with eribulin inhibited EMT marker N-cadherin (Figure 
4C and 4D) as observed in vitro (Figure 1E).
Eribulin and BKM120 synergistically inhibits 
mammosphere formation and stem cell 
population
The effect of eribulin and BKM120 on N-cadherin 
in TNBC cell lines suggest that the combination is 
synergistic in reducing EMT. As EMT is associated with 
cancer cell stemness, we hypothesize that the combination 
therapy is synergistic in reducing the cancer stem cell 
population. We, therefore, examined the effect of eribulin 
and BKM120, alone or in combination, on mammosphere 
formation in low attachment plates as well as on CD44+/
CD24-neg/low sub-population, the putative stem cell 
population, in TNBC cell lines. As demonstrated in Figure 
5, the combination of eribulin and BKM120 inhibited 
mammosphere formation synergistically in BT549, 
and MDA-MB-231, as well as, in the ex-vivo cultured 
WHIM6 and WHIM12-PDX cells. In addition, eribulin 
in combination with BKM120 was more effective than 
each agent alone in reducing the percentage of the CD44+/
CD24neg sub-population in MDA-MB-231 cells (Figure 
6A, 6B). Interestingly, in BT549 cells, treatment with 
eribulin and BKM120 reduced the percentage of CD44+/
CD24-population, with combination therapy being the 
more effective (Figure 6C, 6D). Co-expression of CD44 
and CD24 is frequently observed in basal/epithelial breast 
cancer cells [28] and CD44+/CD24+ cells have shown to 
be more invasive and tumorigenic than CD44+/CD24neg 
cells and possess stemness characteristics of self-renewal 
and differentiation in multiple cancer types [29, 30]. This 
is in contrast to paclitaxel, another microtubule inhibitor, 
which did not inhibit these subsets of cell population, 
either administered alone or in combination with BKM120 
(Supplementary Figure 2).
DISCUSSION
Resistance to chemotherapy is associated with 
poor clinical outcomes in patients with TNBC, for which 
targeted therapies are lacking [1, 31-32]. In this study, we 
demonstrated that PI3K inhibition in combination with an 
anti-mitotic chemotherapy agent eribulin led to enhanced 
target inhibition, reduction of cancer stem cell population, 
and synergistic cytotoxic effect in TNBC cell lines and 
PDX models, providing a preclinical rationale for further 
clinical investigation.
PI3K pathway signaling plays key regulatory 
roles in many cellular processes, including cell survival, 
proliferation, differentiation and angiogenesis [13, 14]. 
Aberrant activation of the PI3K pathway signaling is 
frequently observed in TNBC [15, 21]. Compared to other 
Figure 3: Eribulin in combination with BKM120 inhibits tumor growth in TNBC PDXs. Tumor volume changes with time 
compared to baseline following treatment with either vehicle, eribulin (1 mg/kg, IP, day 1 each week x 3), BKM120 (30 mg/kg, PO, days 
1-5 each week x3) or the combination of eribulin and BKM120 in (A) WHIM6, (B) WHIM12 and (C) WHIM21 TNBC PDX models in 
vivo (n=6). (D) Tumor volume changes with time compared to baseline following treatment with either eribulin (0.3 mg/kg, IP, day 1 each 
week x 3), or the combination of eribulin and BKM120 administered concurrently (eribulin 0.3 mg/kg, IP, day 1 and BKM120 30 mg/kg, 
PO, days 1-5 each week) or sequentially (eribulin 0.3 mg/kg, IP, day 1 followed by BKM120 30 mg/kg, PO, on days 2-5 each week) in 
WHIM21. * indicates p<0.05 and **** indicates p<0.0001.
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subtypes, TNBC is associated with significantly higher 
levels of AKT phosphorylation, as well as, PI3K signaling 
activity assessed by either gene expression signature or 
RPPA phosphoproteomic signature [16, 17, 33]. Common 
PI3K pathway gene abnormalities identified in the TCGA 
TNBC data set included PIK3CA mutation (7%), as well 
as, loss/mutations of PTEN (35%) and loss of INPP4B 
(16%), which are the major causes of pathway signaling 
activation [33]. Consistent with the importance of PI3K 
pathway in TNBC tumorigenesis, PTEN inactivation leads 
to “basal-like” breast cancer in animal models [34, 35].
PI3K pathway signaling activation has been 
identified to be a key resistance mechanism to 
chemotherapy as demonstrated in a recent study which 
investigated genomic alterations and gene expression 
profiles associated with chemotherapy resistance in 
patients with TNBC [36]. In addition, inhibition of PI3K 
pathway components has been shown to enhance the 
sensitivity to various chemotherapy agents in preclinical 
models [26, 37-42]. For example, significant synergisms 
in terms of reducing cell proliferation and induction 
of apoptosis were observed with the combination 
of ipatasertib, an AKT inhibitor, or taselisib, a PI3K 
inhibitor, and anti-microtubule agents including paclitaxel, 
vinorelbine, and eribulin in PIK3CA mutant breast cancer 
cell lines in vitro [40]. Although the first-generation 
mTOR or PI3K inhibitors have generated mixed results 
when combined with paclitaxel in clinical trials [43], 
Figure 4: Eribulin in combination with BKM120 induces more apoptosis, mitotic cell cycle arrest and target inhibition 
in TNBC PDXs. Representative pictures for IHC analysis of Cleaved-PARP and phospho-histone3 (pH3) following 3 days of therapy with 
either vehicle or eribulin and BKM120, alone or in combination are shown for (A) WHIM6 and (B) WHIM21 PDX tumors. Combination 
therapy was associated with enhanced mitotic arrest (pH3) and apoptosis (Cleaved PARP). Western blot analysis for pAKT, AKT and 
N-Cadherin was performed on post treatment tumor lysates for (C) WHIM6 and (D) WHIM21. Abbreviations: V, Vehicle; B, BKM120; E, 
Eribulin; C, Combination. Treatment with single agent BKM120 and eribulin reduced the levels of pAKT and N-Cadherin, respectively. 
The combination of BKM120 and eribulin reduced the levels of both pAKT and N-Cadherin.
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Figure 5: Eribulin alone or in combination with BKM120 inhibited mammosphere formation in TNBC cell lines in 
vitro. Mammosphere formation was assessed following 6 days treatment with either vehicle, eribulin, BKM120, or the combination 
of eribulin and BKM120 for (A) BT549, (B) MDA-MB-231, (C) ex vivo cultured WHIM6 and (D) WHIM12 PDX derived cell line. 
Representative photographs were shown. The combination of eribulin and BKM120 was most in inhibiting mammosphere formation.
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Figure 6: Eribulin in combination with BKM120 inhibited stem cell population in TNBC lines in vitro. Representative 
FACS analysis of stem cell population in (A) MDA-MB-231 and (C) BT549 cells after eribulin and BKM120 single and combination 
treatment for 48 hours. Gates were adjusted using unstained and isotype secondary controls. (B) and (D) shows the quantification of cellular 
subsets by CD44 and CD24 staining for MDA-MB-231 and BT549, respectively, from three independent experiments. * indicates p<0.05 
and ** indicates p<0.01.
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more encouraging data has been observed with direct 
AKT inhibitors in the neoadjuvant [44], as well as, 
metastatic settings for the treatment of TNBC [45]. In 
this paper, we show that BKM120 enhances the cytotoxic 
effect of the non-taxane microtubule inhibitor eribulin 
in TNBC PDX models with loss of PTEN, accompanied 
by enhanced mitotic arrest and apoptosis induction. Our 
data provides in vivo validation for the synergistic effect 
of this combination observed in a cell-based assay [26] 
and is in line with a prior study presented in an abstract 
form in PIK3CA mutant breast cancer xenograft models 
[42]. These results are in support of ongoing and future 
clinical trial investigations of eribulin with PI3K pathway 
inhibitors such as NCT02723877 and NCT02616848 in 
this difficult to treat patient population.
We were particularly interested in eribulin as 
chemotherapy agent because of its unique mechanisms of 
action and potential effect on EMT. There is increasing 
evidence in the literature indicating that CSCs play a 
crucial role in therapy resistance [46-48] and that activation 
of the PI3K/AKT pathway is indispensable for maintaining 
the stemness and chemoresistance of breast CSCs [49, 50]. 
Moreover, previous studies have also shown that PI3K 
inhibition sensitizes CSCs to chemotherapy and molecular 
targeted therapy in several cancers including leukemia, 
hepatocellular carcinoma and breast cancer [51-53]. In this 
study, we showed that BKM120 and eribulin each reduced 
mammosphere formation and CSC population as a single 
agent in vitro, but the combination was more effective. 
We demonstrated that the combination of eribulin and 
BKM120 was most effective in inhibiting downstream 
signaling of PI3K and EMT markers, accompanied by 
enhanced mitotic arrest and apoptosis induction.
The limitations of this study includes the small 
number of PDX models tested and the lack of predictive 
marker biomarkers for the combination of eribulin and 
BKM120. A larger cohort of PDX models are needed for 
biomarker development. In addition, BKM120 is no longer 
being developed clinically due to its associated side effects. 
However, this is a proof of concept study demonstrating 
the potential of eribulin and PI3K inhibitor combinations. 
Future studies will focus on other clinical PI3K inhibitors.
MATERIALS AND METHODS
Chemicals
BKM120 (Catalog no. CT-BKM120) was purchased 
from Chemietek. Eribulin was provided by Eisai. Paclitaxel 
(Catalog no. S1150) was purchased from Selleckchem. All 
drugs were prepared in stock solution of 10 mM in dimethyl 
sulfoxide (DMSO; Sigma) for in vitro experiments.
In vitro cytotoxic assay
For cytotoxic assay, BT549, MDA-MB-231, 
HCC1806, WHIM3, and WHIM12 were seeded at 
a density of 3,000 cells per well in 96-well plates in 
RPMI-1640 medium supplemented with 10% FBS, 
1% glutamine, and 1% penicillin-streptomycin for 24 
hours. Cells were treated with vehicle, or varying doses 
of eribulin (0-1 nM) either alone or in combination with 
BKM120 (500 nM) for 6 days followed by Alamar Blue 
Assay. Each experiment was repeated twice in triplicate. 
Synergistic or additive activity between eribulin and 
BKM120 was determined by calculating combination 
index values using Compu Syn software.
Cell lines
BT549, MDA-MB-231, and HCC1806 were 
purchased from ATCC. WHIM3 (also named WU-BC3) 
and WHIM12 were established from PDX models and 
were described previously [27, 54].
Western blotting
Cell lines treated with eribulin or BKM120 were 
seeded in a 6-well plate at a density of 0.5 × 106, adhered 
overnight and treated with DMSO (0.1%), eribulin at 
5nM and BKM120 at 500 nM concentration for 48 
hours. Cells were then harvested and lysed with 100 
μL buffer containing 50 mmol/L Tris-HCl, pH 7.5, 150 
mmol/L NaCl, 2 mmol/L EDTA, 1% Triton, 1 mmol/L 
phenylmethylsulfonylfluoride, and Protease Inhibitor 
Cocktail (Sigma) for 20 min on ice. Lysates from cell lines 
or PDX xenografts were cleared at 10,000 rpm for 15 min, 
boiled, separated on 12% SDS gels, and transferred to a 
nitrocellulose membrane followed by overnight incubation 
with primary antibodies against pAKT473, AKT, pS6240/244, 
S6, N-Cadherin, cleaved PARP, survivin (BRIC5) and 
β-actin. Protein bands were visualized after 1 hour 
incubation with HRP-conjugated secondary antibodies and 
development with ECL (GE Healthcare).
Primary antibodies against phospho-AKTS473 (Cat. 
no. 4060), AKT (Cat. no. 4685), phospho- S6Ser240/244 (Cat. 
no. 2215), S6 (Cat. no. 2217), Cleaved PARP (Asp214) 
(Cat. no. 9541), and β-actin (Cat. no. 4970) were purchased 
from Cell Signaling Technology. Other primary antibodies 
included antibodies against N-Cadherin (Cat. no. ab18203; 
Abcam), survivin (Cat. no. sc-17779; Santa Cruz), and p21 
(Cat. no. sc-6246; Santa Cruz). Secondary horseradish 
peroxidase (HRP)-conjugated anti-rabbit (Cat.7074) and 
anti-mouse antibodies (Cat. no. 7076) for Western Blot 
were purchased from Cell Signaling Technology.
Flow cytometry cell cycle analysis
BT549, MDA-MB-231 and WHIM12 cells were 
seeded in 6-well plate at a density of 500,000 cells/
well in 2ml RPMI medium. After 24 hours, cells were 
treated with vehicle, or BKM120 (500nM) and eribulin 
(5nM), either alone or in combination for 48 hours. Cells 
were then harvested and analyzed for cell cycle analysis 
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using Invitrogen Propidium Iodide staining buffer. Data 
from three independent experiments were used for the 
quantification of cellular subsets in Figure 6B, Figure 6D, 
Supplementary Figure 2B, and Supplementary Figure 2D.
Immunohistochemistry
IHC for pHistone H3 and cleaved PARP were 
conducted on 5 μm tissue sections from paraffin-
embedded tumor as described previously using the 
EnVision + Single Reagents HRP-Rabbit (Dako) and 
REAL substrate buffer (REAL DAB + chromogen, Dako) 
[54]. The primary antibodies and dilutions are as follows: 
pHistone H3 (Ser 10) antibody (1:200; Cat. no. 06-570; 
Millipore), and cleaved PARP antibody (1:200, Cat. no. 
9541; Cell Signaling).
Analysis of CD44+ /CD24– cell subpopulation
Cells were seeded in a 6-well plate at a density 
of 0.5 × 106, adhered overnight, followed by treatment 
with DMSO (0.1 %), eribulin at 5nM and BKM120 at 
500 nM concentration for 48 hours. After 48 hours, cells 
were harvested for CD44/C24 expression analysis by 
FACS. To evaluate CD24 and CD44 expression, cells 
were harvested, washed with FCS buffer once. Then, 
100,000 cells again resuspended in 1ml FCS buffer and 
antibodies against CD44-PE (10ul) (Cat. no. 555479; BD 
Pharmingen) and CD24 Alexa-Flour 647- (2.5ul) (Cat. no. 
311109; BioLegend) were added for 30 minutes at room 
temperature in the dark. After 30 minutes, cells were 
washed with PBS two times and resuspended in 1ml FCS 
buffer and analyzed by FACS. Then cells were analyzed 
on a BD FACS Calibur flow cytometer. These data were 
analyzed by Flo-Jo and at least 10,000 events per sample 
were collected. Appropriate controls were included in 
the experiments. Unstained samples, Isotype-Secondary 
control, CD44 and CD24 alone staining.
Mammosphere culture
Sphere formation was performed in ultralow 
attachment 6-well plates (Corning) with DMEM/F12 stem 
cell medium. (Thermo scientific). BT549, MDA-MB-231, 
WHIM12 and WHIM6-PDX derived cells were seeded at 
the density around 1000 cells/well in ultralow attachment 
6-well plates and cultured at 37°C in 5% CO2. After 24 
hours, cells were treated with vehicle, BK1M20 (500nM) 
and Eribulin (5nM) for 6 days. Colony formation was 
assessed and photomicrograph after 6 days of treatment.
In vivo xenografts-drug therapy and assessment
PDX models were passaged on each side of the 
fourth mammary fat pad in female NU/J homozygous mice 
(Charles River Cat. No. 088) to propagate xenografts for 
tumor growth and biomarker response with drug therapy. 
For the initial screening experiments, 6 PDX models 
with each passaged in 1-3 mice were allowed to grow to 
approximately 1 cm in diameter, then treated with eribulin 
(0.75 mg/kg, IP days 1, 3 and 8) and BKM120 (30 mg/kg, 
PO, days 1-5 then days 7-8). For tumor growth experiments 
shown in Figure 3A-3C, xenografts were allowed to grow 
to approximately 0.5 cm in the maximum diameter. Mice 
were then divided into 4 treatment groups (n = 6 mice in 
each group): Vehicle (vehicle diluents were 0.9% sodium 
chloride saline for eribulin and 0.5% (w/v) methyl cellulose 
0.5% (v/v) Tween 80 in water for BKM120), eribulin alone 
(1 mg/kg, IP on day 1 each week), BKM120 alone (30mg/
kg, oral gavage, days 1-5 each week) or the combination of 
eribulin and BKM120 (at the same dose and schedule as in 
single agent therapy) for a total of 3 weeks. For WHIM21 
tumor response shown in Figure 3D, tumor bearing 
mice (n=6 per group) were treated with either eribulin 
(0.3mg/kg) or the combination of eribulin and BKM120 
concurrently (eribulin 0.3 mg/kg, IP, day 1 and BKM120 
30 mg/kg, PO, days 1-5 each week) or sequentially 
(eribulin 0.3 mg/kg, IP, day 1 followed by BKM120 30 
mg/kg, PO, on days 2-5 each week) for 3 weeks. Two 
dimensional measurements (length and width) using 
Traceable Digital Calipers were performed 2-3 times each 
week. The following formula was used to calculate tumor 
volume: tumor volume (cm3) = (length × width2) × 0.5. For 
biomarker studies tumor bearing mice were treated with 
either Vehicle (n = 2), eribulin (n=2; 1 mg/kg/day,IP day1), 
BKM120 (n=2, 30 mg/kg, days 1, 2, 3), or the combination 
of eribulin and BKM120 (the same dosing and schedule 
as single agent therapy). Tumors were harvested 2 hours 
after day 3 of therapy. Each xenograft tumor was cut into 
2 pieces with one piece flash frozen for tumor lysate, and 
the second piece fixed in 10% neutral buffered formalin 
and embedded in paraffin blocks. All animal studies were 
carried out using the appropriate NIH animal care, and 
the animal studies protocol was approved by the Animal 
Studies Committee of Washington University.
Statistical analysis
Statistical analyses were conducted using Graphpad 
Prism software. Results are expressed as mean ± SEM. 
Statistical significance was determined by Student paired 
t test for in vitro data respectively. Tumor volume data 
were compared using two-way ANOVA. P ≤ 0.05 was 
considered significant.
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